BGNE - BeiGene's Poster For Upcoming Conference Reveals Promising Lung Cancer Data | Benzinga
BeiGene Ltd's (NASDAQ: BGNE) Phase 3 RATIONALE 315 study met its dual primary endpoints of major pathological response (MPR) by Blinded Independent Pathology Review (BIPR) and event-free survival (EFS).
RATIONALE 315 Phase 3 trial evaluated neoadjuvant tislelizumab plus platinum-based doublet chemotherapy, followed by surgery and subsequent adjuvant tislelizumab, compared to placebo plus neoadjuvant platinum-based doublet chemotherapy followed by surgery and subsequent adjuvant placebo for resectable Stage II or IIIA Non-Small Cell Lung Cancer (NSCLC).
Also Read: Chinese Drugmaker BeiGene And Novartis Move Out From ...